Objective To investigate the efficacy of venlafaxine combined with Daily Naikan therapy in treatment residual symptoms of major depression.
Methods 60 patients with major depression being residual symptoms episodes were treated with venlafaxine for 6 weeks(7≦HAMD−17<17)and were randomly treated with venlafaxine combined with Daily Naikan therapy and venlafaxine for 4th weeks respectively. At the baseline and end of fourth week of treatment, Hamilton Depression Scale−17(HAMD−17)and Clinical Global Impression(CGI)、Life Satisfaction Rating Scale(LSR) were employed to evaluated the clinical efficacy.
Results There were no significant difference in HAMD-17, CGI, the LSR score between two group at the baseline(P>0.05);At the end 4th week of treatment, HAMD−17 reduced score of study group was significantly higher than control group(6.30±3.37:5.93±3.62;P=0.01);CGI-S reduced score of study group was significantly higher than control group(0.85±0.41:0.56±0.49;P =0.004);LSR increased score of study group was significantly higher than control group(3.04±0.87:2.16±0.53;P=0.02), and each factor increased score of study group was also significantly higher than control group(P<0.05).
Conclusions Compared with venlafaxine, venlafaxine combined with Naikan therapy may have better effect than venlafaxine monotherapy in treatment residual symptoms of major depression and may have better improvement of the life satisfaction.
View full abstract